Miltefosine and Benznidazole Combination Improve Anti-

Animals Chagas Disease / drug therapy Mice Nitroimidazoles Parasitemia / drug therapy Phosphorylcholine / analogs & derivatives Trypanocidal Agents / pharmacology Trypanosoma cruzi
Chagas disease Trypanosoma cruzi benznidazole drug combination chemotherapy drug repositioning miltefosine

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2022
Historique:
received: 14 01 2022
accepted: 16 05 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 26 7 2022
Statut: epublish

Résumé

Drug repurposing and combination therapy have been proposed as cost-effective strategies to improve Chagas disease treatment. Miltefosine (MLT), a synthetic alkylphospholipid initially developed for breast cancer and repositioned for leishmaniasis, is a promising candidate against

Identifiants

DOI: 10.3389/fcimb.2022.855119 PMID: 35865815 PMC: PMC9294734
pubmed: 35865815
doi: 10.3389/fcimb.2022.855119
pmc: PMC9294734
doi:

Substances chimiques

Nitroimidazoles 0
Trypanocidal Agents 0
Phosphorylcholine 107-73-3
miltefosine 53EY29W7EC
benzonidazole YC42NRJ1ZD

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

855119

Informations de copyright

Copyright © 2022 Gulin, Bisio, Rocco, Altcheh, Solana and García-Bournissen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Elife. 2018 Mar 26;7:
pubmed: 29578409
Antimicrob Agents Chemother. 2002 Nov;46(11):3472-7
pubmed: 12384352
Lipids. 1987 Nov;22(11):925-6
pubmed: 3444386
Indian J Pediatr. 2006 Dec;73(12):1077-80
pubmed: 17202633
J Antimicrob Chemother. 2012 Nov;67(11):2576-97
pubmed: 22833634
N Engl J Med. 1999 Dec 9;341(24):1795-800
pubmed: 10588964
Antimicrob Agents Chemother. 2006 Jan;50(1):73-9
pubmed: 16377670
N Engl J Med. 2002 Nov 28;347(22):1739-46
pubmed: 12456849
Parasitol Res. 2012 Jan;110(1):31-5
pubmed: 21584629
Microorganisms. 2021 Feb 16;9(2):
pubmed: 33669310
Antimicrob Agents Chemother. 1993 Sep;37(9):1993-6
pubmed: 8239619
Infect Immun. 1994 May;62(5):1820-9
pubmed: 8168945
J Antimicrob Chemother. 2008 Jun;61(6):1319-27
pubmed: 18343804
Future Med Chem. 2013 Oct;5(15):1733-52
pubmed: 24144410
J Antimicrob Chemother. 2013 Dec;68(12):2834-8
pubmed: 23833177
Acta Trop. 2020 Nov;211:105606
pubmed: 32598923
Drug Des Devel Ther. 2010 Sep 24;4:243-53
pubmed: 20957215
Antimicrob Agents Chemother. 2004 Nov;48(11):4097-102
pubmed: 15504827
Lancet. 2018 Jan 6;391(10115):82-94
pubmed: 28673423
J Antimicrob Chemother. 2005 May;55(5):780-4
pubmed: 15790672
Comp Biochem Physiol A Mol Integr Physiol. 2007 Apr;146(4):601-20
pubmed: 16626984
Int J Parasitol Drugs Drug Resist. 2014 Mar 24;4(2):95-111
pubmed: 25057459
J Med Chem. 2013 Dec 27;56(24):10158-70
pubmed: 24304150
Clin Infect Dis. 2019 Apr 24;68(9):1530-1538
pubmed: 30188978
Clin Pharmacokinet. 2018 Feb;57(2):151-176
pubmed: 28756612
ILAR J. 2000;41(2):99-104
pubmed: 11406703
Am J Trop Med Hyg. 2001 Aug;65(2):152-8
pubmed: 11508392
Exp Parasitol. 2018 Mar;186:50-58
pubmed: 29448038
Nat Rev Microbiol. 2017 Feb 27;15(4):217-231
pubmed: 28239154
PLoS One. 2014 Jan 17;9(1):e85706
pubmed: 24465654
Front Cell Infect Microbiol. 2020 Feb 14;10:46
pubmed: 32133302
PLoS Negl Trop Dis. 2019 Oct 24;13(10):e0007694
pubmed: 31647811
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
J Antimicrob Chemother. 1996 Dec;38(6):1041-7
pubmed: 9023651
Drug Des Devel Ther. 2015 Aug 19;9:4807-23
pubmed: 26316715
Mem Inst Oswaldo Cruz. 2010 Mar;105(2):233-8
pubmed: 20428688
J Antimicrob Chemother. 2014 Jan;69(1):150-4
pubmed: 23970484
Cancer Chemother Pharmacol. 1992;31(1):18-22
pubmed: 1458555
Lab Anim (NY). 2005 Oct;34(9):39-43
pubmed: 16195737
PLoS Negl Trop Dis. 2013;7(1):e2000
pubmed: 23350002
Biomedica. 2009 Sep;29(3):448-55
pubmed: 20436996
Mini Rev Med Chem. 2005 May;5(5):499-519
pubmed: 15892691
J Antimicrob Chemother. 2001 May;47(5):537-46
pubmed: 11328763
PLoS One. 2017 Oct 3;12(10):e0185504
pubmed: 28972996
Drug Des Devel Ther. 2011 Mar 16;5:175-81
pubmed: 21552487
Exp Parasitol. 2010 Feb;124(2):172-80
pubmed: 19747482
Mem Inst Oswaldo Cruz. 2010 May;105(3):239-45
pubmed: 20512235
Acta Trop. 2015 Dec;152:8-16
pubmed: 26272680
Acta Trop. 2000 Mar 25;75(2):219-28
pubmed: 10708662
Acta Trop. 2014 Feb;130:112-6
pubmed: 24239532
Muscle Nerve. 2012 Oct;46(4):582-7
pubmed: 22987701
Parasitol Res. 2016 Oct;115(10):3881-7
pubmed: 27249967
Expert Opin Drug Discov. 2020 Jun;15(6):647-658
pubmed: 32202449

Auteurs

Julián Ernesto Nicolás Gulin (JEN)

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud, Buenos Aires, Argentina.
Instituto de Investigaciones Biomédicas (INBIOMED), Facultad de Medicina Universidad de Buenos Aires (UBA) - CONICET, Buenos Aires, Argentina.

Margarita María Catalina Bisio (MMC)

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud, Buenos Aires, Argentina.
Instituto Nacional de Parasitología (INP) 'Dr. Mario Fatala Chaben'-Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) 'Dr. Carlos G. Malbrán', CONICET, Buenos Aires, Argentina.

Daniela Rocco (D)

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud, Buenos Aires, Argentina.

Jaime Altcheh (J)

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud, Buenos Aires, Argentina.

María Elisa Solana (ME)

Instituto de Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires, Buenos Aires, Argentina.
Departamento de Ciencias Básicas, Universidad Nacional de Luján, Buenos Aires, Argentina.

Facundo García-Bournissen (F)

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud, Buenos Aires, Argentina.
Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Infection › Maladies vectorielles › Maladie de Chagas › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Nitroimidazoles › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Parasitémie › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Composés chimiques organiques › Composés onium › Composés d'ammonium quaternaire › Choline › Phosphoryl-choline › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiparasitaires › Antiprotozoaires › Trypanocides › Miltefosine and Benznidazole Combination Improve Anti-
questionsmedicales.fr › Eucaryotes › Euglénozoaires › Kinetoplastida › Trypanosomatina › Trypanosoma › Trypanosoma cruzi › Miltefosine and Benznidazole Combination Improve Anti-